Literature DB >> 17115966

Off-label use of medicines: consensus recommendations for evaluating appropriateness.

Madlen Gazarian1, Maria Kelly, John R McPhee, Linda V Graudins, Robyn L Ward, Terence J Campbell.   

Abstract

Off-label prescribing is the prescription of a registered medicine for a use that is not included in the product information. The practice is common, with rates up to 40% in adults and up to 90% in paediatric patients. Off-label prescribing is not illegal and may sometimes be clinically appropriate, but is associated with a number of clinical, safety and ethical issues. To date, no explicit guidance has been available to help clinicians assess appropriateness in off-label prescribing. We describe the development of a guide for clinicians, policymakers and funders of health care in evaluating the appropriateness of medicines proposed for off-label use. Three broad categories of appropriate off-label use are identified:off-label use justified by high-quality evidence; use within the context of a formal research proposal; and exceptional use, justified by individual clinical circumstances. An appropriate process for informed consent is proposed for each category. If there is no high-quality evidence supporting off-label use, and the medicine is not suitable for exceptional or research indications, its use is generally not recommended. This will reduce inappropriate use, enhance patient safety by reducing exposure to unnecessary risk, and may stimulate more clinically relevant medicines research.

Entities:  

Mesh:

Year:  2006        PMID: 17115966     DOI: 10.5694/j.1326-5377.2006.tb00689.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  41 in total

Review 1.  Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.

Authors:  Rosa Lerose; Pellegrino Musto; Michele Aieta; Carla Papa; Alfredo Tartarone
Journal:  Eur J Clin Pharmacol       Date:  2011-12-14       Impact factor: 2.953

2.  Unlicensed and off-label drug use in hospitalized children in Croatia: a cross-sectional survey.

Authors:  Goran Palčevski; Nataša Skočibušić; Vera Vlahović-Palčevski
Journal:  Eur J Clin Pharmacol       Date:  2012-02-04       Impact factor: 2.953

3.  Concerns about quetiapine.

Authors:  Alan Garrity
Journal:  Aust Prescr       Date:  2015-12-01

4.  Paediatric clinical pharmacology: at the beginning of a new era.

Authors:  Kalle Hoppu
Journal:  Eur J Clin Pharmacol       Date:  2007-10-31       Impact factor: 2.953

5.  Challenges in international pediatric pharmacology: a milestone meeting in Shanghai.

Authors:  Stuart MacLeod; Robert Peterson; Yi Wang; Zhiping Li; Yonghao Gui; Jane Schaller
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

6.  Funding a clinical trial: the perspective of a medicines funder.

Authors:  Peter Alsop; Scott Metcalfe; Jackie Evans
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 7.  Administration of dry powders during respiratory supports.

Authors:  Wei-Ren Ke; Rachel Yoon Kyung Chang; Philip Chi Lip Kwok; Patricia Tang; Lan Chen; Donghao Chen; Hak-Kim Chan
Journal:  Ann Transl Med       Date:  2021-04

Review 8.  Two decades of off-label prescribing in children: a literature review.

Authors:  Shamala Balan; Mohamed Azmi Ahmad Hassali; Vivienne S L Mak
Journal:  World J Pediatr       Date:  2018-09-14       Impact factor: 2.764

Review 9.  [Off-label use of drugs in pediatric emergencies: limitations and grey areas of drug approval].

Authors:  C G Erker; M Möllmann
Journal:  Anaesthesist       Date:  2013-02       Impact factor: 1.041

10.  Prescribing gabapentin off label: Perspectives from psychiatry, pain and neurology specialists.

Authors:  Christine Fukada; Jillian Clare Kohler; Heather Boon; Zubin Austin; Murray Krahn
Journal:  Can Pharm J (Ott)       Date:  2012-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.